The Hydration Pharmaceuticals Company Limited (ASX: HPC) share price has had a great start to its time on the ASX.
The company debuted on the market yesterday after an initial public offering (IPO) that saw its shares going for 29 cents apiece.
At the time of writing, the Hydration Pharmaceuticals Company share price is 38 cents, 7.04% higher than when it experienced its first closing bell.
That means shareholders who got in on the company’s prospectus offer have seen their investment grow by 31% already.
Let’s take a closer look at the ASX newbie and how it’s been performing so far.
What does the company do?
The Hydration Pharmaceuticals Company – more colloquially known as Hydralyte North America – is responsible for a popular household brand that many readers will know well.
That is, Hydralyte – which offers electrolyte-rich powders, drinks, and tablets. Though, the company doesn’t sell Hydralyte products in Australia or New Zealand.
Instead, it has rights to market the products in America, Europe (but not Turkey), China (but not Taiwan), and Hong Kong.
Hydration Pharmaceuticals Company share price soars following IPO
The Hydration Pharmaceuticals Company hit the ASX at noon on Tuesday, when its share price soared to 35.5 cents on the day.
The company raised $17 million during its IPO by selling approximately 58.6 million shares.
Most of the funds raised through its IPO will fund its sales and marketing. Though, some will be spent on brand and product development.
Over the 12 months ended 30 September 2020, the company brought in around US$3 million of pro forma revenue. It also saw a pro forma after-tax loss of around US$5.9 million.
For the 12 months ended 30 September 2021, Hydration predicts it will see approximately US$5.4 million of pro forma revenue and a pro forma after-tax loss of around US$6.7 million.
The directors have no intention of paying a dividend soon, though, due to the company being in the development stage.
The company’s IPO offer price would have seen it with a market capitalisation of around $46.7 million.
At its current share price, The Hydration Pharmaceuticals Company has a valuation of approximately $61.2 million.
The post Hydration Pharmaceuticals (ASX:HPC) share price rockets 31% in 2 days following IPO appeared first on The Motley Fool Australia.
Should you invest $1,000 in The Hydration Pharmaceutical Company right now?
Before you consider The Hydration Pharmaceutical Company, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and The Hydration Pharmaceutical Company wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- Fees for no service? ASIC lawsuit against Insignia (ASX:IFL) for potential misconduct
- Here’s why the Antisense (ASX:ANP) share price is climbing 5% today
- Here are the 3 most heavily traded ASX 200 shares this Wednesday
- Two inflation resilient ASX 200 shares revealed: fund manager
- Here’s why the Challenger (ASX:CGF) share price has lifted today
The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3yuiAGA
Leave a Reply